Robert Besthof - 08 Mar 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: Interim CEO
Issuer ticker: NRXP
Reported as of: 08 Mar 2022
Net transaction value: +$261,000
SEC form: 4
Accepted by SEC: 10 Mar 2022, 15:04:19 UTC
Prior SEC filing: 02 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Robert Besthof

Key filing fact

Robert Besthof filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 10 Mar 2022.

Key facts

This page summarizes Robert Besthof's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2022, 15:04.

Change

Previous filing in this sequence was filed on 02 Nov 2021.
Current net transaction value: +$261,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRXP transaction Derivative

Employee Stock Option

Award

Transaction value: $261,000
Shares: +100,000
Change %: +40%
Price: $2.61^*
Shares after: 347,200
Date: 08 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc.